secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-08-12T12:30:57+00:00
Accession:  0001829126-26-008654
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc NEO100 Phase 2a meets primary endpoint: PFS-6 48.9% vs 20% benchmark
--------------------------------------------------------------------------

- PFS-6 48.9% (95% CI 26.3-68.1) vs 20% SOC benchmark, p=0.0047; median PFS 3.91 mo.
- Median OS 26.09 months; OS rates 86.7% at 6 mo, 60.9% at 12 mo, 54.1% at 24 mo.
- 5 of 24 patients remain on treatment; one progression-free ~19 mo, one partial response 114 days; ORR 8.3%.
- No major toxicities; adverse events predominantly low-grade; self-administered intranasally at home.
- Company to request Type B FDA meeting to align on registrational path; full data at future medical meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626008654/0001829126-26-008654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626008654/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-008654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer